دورية أكاديمية
Long COVID as a disease of accelerated biological aging: An opportunity to translate geroscience interventions.
| العنوان: | Long COVID as a disease of accelerated biological aging: An opportunity to translate geroscience interventions. |
|---|---|
| المؤلفون: | Shafqat A; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Electronic address: ashafqat@alfaisal.edu., Masters MC; Division of Infectious Diseases, Northwestern University, Chicago, IL, USA., Tripathi U; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA., Tchkonia T; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA., Kirkland JL; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA., Hashmi SK; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; Research and Innovation Center, Department of Health, Abu Dhabi, UAE; College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates. |
| المصدر: | Ageing research reviews [Ageing Res Rev] 2024 Jun 28; Vol. 99, pp. 102400. Date of Electronic Publication: 2024 Jun 28. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: England NLM ID: 101128963 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9649 (Electronic) Linking ISSN: 15681637 NLM ISO Abbreviation: Ageing Res Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford, UK : Elsevier Science, c2002- |
| مستخلص: | It has been four years since long COVID-the protracted consequences that survivors of COVID-19 face-was first described. Yet, this entity continues to devastate the quality of life of an increasing number of COVID-19 survivors without any approved therapy and a paucity of clinical trials addressing its biological root causes. Notably, many of the symptoms of long COVID are typically seen with advancing age. Leveraging this similarity, we posit that Geroscience-which aims to target the biological drivers of aging to prevent age-associated conditions as a group-could offer promising therapeutic avenues for long COVID. Bearing this in mind, this review presents a translational framework for studying long COVID as a state of effectively accelerated biological aging, identifying research gaps and offering recommendations for future preclinical and clinical studies. Competing Interests: Declaration of Competing Interest S.K.H received Honoraria/grants from Pfizer, Novartis, Janssen, Therakos Mallinckrodt, and Sanofi and Roche. T.T and J.L.K have a financial interest related to this research, including patents and pending patients covering senolytic drugs and their uses that are held by Mayo Clinic. The remaining authors declare no competing interests. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Cellular Senescence; Dysbiosis; Geroscience; Inflammation; Long COVID; Mitochondrial Dysfunction |
| تواريخ الأحداث: | Date Created: 20240630 Latest Revision: 20240711 |
| رمز التحديث: | 20240712 |
| DOI: | 10.1016/j.arr.2024.102400 |
| PMID: | 38945306 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1872-9649 |
|---|---|
| DOI: | 10.1016/j.arr.2024.102400 |